《Journal Of Physiology And Pharmacology》雜志的收稿范圍和要求是什么?
來(lái)源:優(yōu)發(fā)表網(wǎng)整理 2024-09-18 11:01:08 446人看過(guò)
《Journal Of Physiology And Pharmacology》雜志收稿范圍涵蓋醫(yī)學(xué)全領(lǐng)域,此刊是該細(xì)分領(lǐng)域中屬于非常不錯(cuò)的SCI期刊,在行業(yè)細(xì)分領(lǐng)域中學(xué)術(shù)影響力較大,專業(yè)度認(rèn)可很高,所以對(duì)原創(chuàng)文章要求創(chuàng)新性較高,如果您的文章質(zhì)量很高,可以嘗試。
平均審稿速度 較慢,6-12周 ,影響因子指數(shù)2。
該期刊近期沒有被列入國(guó)際期刊預(yù)警名單,廣大學(xué)者值得一試。
具體收稿要求需聯(lián)系雜志社或者咨詢本站客服,在線客服團(tuán)隊(duì)會(huì)及時(shí)為您答疑解惑,提供針對(duì)性的建議和解決方案。
出版商聯(lián)系方式:POLISH PHYSIOLOGICAL SOC, JAGIELLONIAN UNIV SCHOOL MED, INST PHYSIOLOGY, 31-531 KRAKOW, GRZEGORZECKA, POLAND, 16
其他數(shù)據(jù)
是否OA開放訪問: | h-index: | 年文章數(shù): |
開放 | 70 | 59 |
Gold OA文章占比: | 2021-2022最新影響因子(數(shù)據(jù)來(lái)源于搜索引擎): | 開源占比(OA被引用占比): |
0.00% | 2 | 0 |
研究類文章占比:文章 ÷(文章 + 綜述) | 期刊收錄: | 中科院《國(guó)際期刊預(yù)警名單(試行)》名單: |
88.14% | SCIE | 否 |
歷年IF值(影響因子):
歷年引文指標(biāo)和發(fā)文量:
歷年中科院JCR大類分區(qū)數(shù)據(jù):
歷年自引數(shù)據(jù):
發(fā)文統(tǒng)計(jì)
2023-2024國(guó)家/地區(qū)發(fā)文量統(tǒng)計(jì):
國(guó)家/地區(qū) | 數(shù)量 |
Poland | 148 |
Slovakia | 21 |
GERMANY (FED REP GER) | 19 |
South Korea | 18 |
CHINA MAINLAND | 11 |
Romania | 8 |
Czech Republic | 6 |
Italy | 6 |
Brazil | 5 |
Egypt | 5 |
2023-2024機(jī)構(gòu)發(fā)文量統(tǒng)計(jì):
機(jī)構(gòu) | 數(shù)量 |
JAGIELLONIAN UNIVERSITY | 44 |
POLISH ACADEMY OF SCIENCES | 19 |
POZNAN UNIVERSITY OF MEDICAL SCI... | 15 |
MEDICAL UNIVERSITY LODZ | 14 |
SLOVAK ACADEMY OF SCIENCES | 14 |
MEDICAL UNIVERSITY SILESIA | 13 |
COMENIUS UNIVERSITY BRATISLAVA | 12 |
MEDICAL UNIVERSITY OF BIALYSTOK | 12 |
POMERANIAN MEDICAL UNIVERSITY | 9 |
CHUNGBUK NATIONAL UNIVERSITY | 8 |
近年引用統(tǒng)計(jì):
期刊名稱 | 數(shù)量 |
J PHYSIOL PHARMACOL | 228 |
PLOS ONE | 59 |
J BIOL CHEM | 43 |
ENDOCRINOLOGY | 38 |
CIRCULATION | 37 |
NATURE | 31 |
HYPERTENSION | 29 |
P NATL ACAD SCI USA | 29 |
AM J PHYSIOL-HEART C | 28 |
J CLIN INVEST | 28 |
近年被引用統(tǒng)計(jì):
期刊名稱 | 數(shù)量 |
J PHYSIOL PHARMACOL | 228 |
INT J MOL SCI | 100 |
SCI REP-UK | 51 |
NUTRIENTS | 38 |
PLOS ONE | 29 |
MOLECULES | 28 |
OXID MED CELL LONGEV | 28 |
EUR J PHARMACOL | 24 |
J CELL BIOCHEM | 20 |
J CELL PHYSIOL | 19 |
近年文章引用統(tǒng)計(jì):
文章名稱 | 數(shù)量 |
OXIDATIVE STRESS AND INFLAMMATOR... | 19 |
WNT SIGNALING PATHWAY IN DEVELOP... | 17 |
SPERM MITOCHONDRIAL DYSFUNCTION ... | 15 |
THE IMPORTANCE OF SELECTED MARKE... | 15 |
MYOKINE IRISIN-INDUCED PROTECTIO... | 11 |
PHARMACOLOGICAL AND DIETARY FACT... | 9 |
THE IMPLICATION OF ADIPOCYTE ATP... | 9 |
THE ROLE OF LOW-CALORIE DIETS AN... | 9 |
THE CYCLOOXYGENASE-2/PROSTAGLAND... | 8 |
CHARACTERIZATION AND BIOLOGICAL ... | 8 |
聲明:以上內(nèi)容來(lái)源于互聯(lián)網(wǎng)公開資料,如有不準(zhǔn)確之處,請(qǐng)聯(lián)系我們進(jìn)行修改。